search
Back to results

Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain

Primary Purpose

Chronic Low Back Pain

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Bicifadine
Sponsored by
DOV Pharmaceutical, Inc.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Low Back Pain focused on measuring bicifadine, chronic low back pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria: Patients with low back pain assessed as Class 1, Class 2 or Class 3 according to the Quebec Task Force Classification for Spinal Disorders and without detectable leg weakness on neurological examination. Patients with pain categorized as Class 1 according to the Quebec Task Force Classification must have a Roland-Morris Disability Rating of >17 at baseline to qualify. Patients with pain categorized as Class 2 or Class 3 according to the Quebec Task Force Classification must have a Roland-Morris Disability Rating of at least 10 at baseline to qualify. Patients must have required daily analgesics for the treatment of low back pain for at least 3 months prior dosing. Main Exclusion Criteria: Patients may not have persistent moderate or severe pain in a location other than the lower back (with the exception of radiation to the lower extremity). Patients must not have had lower back surgery within 6 months prior to baseline, nor epidural corticosteroid injections within 3 months prior to baseline. Patients may not have an unstable medical condition.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Pain Severity Rating (100 mm visual analog scale)

    Secondary Outcome Measures

    Short-Form McGill Pain Questionnaire (SF-MPQ)
    Roland-Morris Disability Questionnaire (RDQ)
    Short-Form 36 (SF-36) Health Survey
    Patient's Global Impression of Change (7-point categorical scale)

    Full Information

    First Posted
    February 23, 2006
    Last Updated
    January 26, 2007
    Sponsor
    DOV Pharmaceutical, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00295724
    Brief Title
    Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain
    Official Title
    A Multi-Center, Double-Blind, Placebo-Controlled Randomized Study of Bicifadine 200 mg BID in the Treatment of Chronic Low Back Pain
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2007
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2005 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    DOV Pharmaceutical, Inc.

    4. Oversight

    5. Study Description

    Brief Summary
    The primary objectives of this placebo-controlled clinical trial are to evaluate the analgesic efficacy and safety of bicifadine 200 mg BID compared with placebo in patients with moderate to severe chronic low back pain. The secondary objectives are to evaluate the effect of bicifadine on function and general quality of life, to evaluate safety following discontinuation of bicifadine treatment and to investigate the population pharmacokinetics of bicifadine.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Chronic Low Back Pain
    Keywords
    bicifadine, chronic low back pain

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Bicifadine
    Primary Outcome Measure Information:
    Title
    Pain Severity Rating (100 mm visual analog scale)
    Secondary Outcome Measure Information:
    Title
    Short-Form McGill Pain Questionnaire (SF-MPQ)
    Title
    Roland-Morris Disability Questionnaire (RDQ)
    Title
    Short-Form 36 (SF-36) Health Survey
    Title
    Patient's Global Impression of Change (7-point categorical scale)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Main Inclusion Criteria: Patients with low back pain assessed as Class 1, Class 2 or Class 3 according to the Quebec Task Force Classification for Spinal Disorders and without detectable leg weakness on neurological examination. Patients with pain categorized as Class 1 according to the Quebec Task Force Classification must have a Roland-Morris Disability Rating of >17 at baseline to qualify. Patients with pain categorized as Class 2 or Class 3 according to the Quebec Task Force Classification must have a Roland-Morris Disability Rating of at least 10 at baseline to qualify. Patients must have required daily analgesics for the treatment of low back pain for at least 3 months prior dosing. Main Exclusion Criteria: Patients may not have persistent moderate or severe pain in a location other than the lower back (with the exception of radiation to the lower extremity). Patients must not have had lower back surgery within 6 months prior to baseline, nor epidural corticosteroid injections within 3 months prior to baseline. Patients may not have an unstable medical condition.

    12. IPD Sharing Statement

    Learn more about this trial

    Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain

    We'll reach out to this number within 24 hrs